Long-term Urological Outcomes in Patients with Posterior Urethral Valves: A Comprehensive Review of Transitional Care Challenges from Prenatal Diagnosis to Adulthood
Dr. Vivek Viswanathan *
*Correspondence to: Dr. Vivek Viswanathan, Consultant Paediatric Urology and Surgery, Assistant Professor, Department of Paediatric Surgery, Dhiraj Hospital, Sumandeep Vidyapeeth, Vadodara, India.
Copyright
© 2026: Dr. Vivek Viswanathan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 17 June 2026
Published: 01 July 2026
DOI: https://doi.org/10.5281/zenodo.21093388
Abstract
Background: Posterior urethral valves (PUV) constitute the single most frequent cause of congenital lower urinary tract obstruction in male neonates, with a reported incidence of approximately 1 in 3000 to 8000 live births. Advances in prenatal sonography, neonatal intensive care, and endoscopic surgical techniques have substantially reduced early mortality; however, the resulting cohort of survivors faces lifelong urological and renal sequelae that necessitate structured, multidisciplinary transitional care programmes.
Objectives: This review aims to synthesise contemporary evidence regarding the natural history of PUV across the lifespan, evaluate the adequacy of existing transitional care frameworks, and propose evidence-informed recommendations for the monitoring and management of young adults with a history of PUV.
Methods: A narrative review of peer-reviewed literature was conducted using PubMed, MEDLINE, and EMBASE databases. Search terms included 'posterior urethral valves', 'valve bladder syndrome', 'transitional urology', 'chronic kidney disease paediatric', and 'urodynamics PUV'. Studies published between 1980 and 2024 addressing prenatal outcomes, surgical management, bladder dysfunction, renal impairment, and transitional care in PUV patients were included.
Results: Antenatal ultrasound facilitates diagnosis in the majority of contemporary cases, though prenatal intervention via vesicoamniotic shunting yields only marginal long-term renal benefit. Transurethral valve ablation remains the definitive early treatment. Despite successful ablation, a substantial proportion of patients develop valve bladder syndrome, characterised by detrusor dysfunction that evolves from hyperreflexia in childhood to myogenic failure in adolescence and adulthood. Approximately 22% of PUV patients progress to chronic kidney disease (CKD) and 11% to end-stage renal disease (ESRD). Structured urodynamic surveillance, anticholinergic therapy, clean intermittent catheterisation, and, in refractory cases, augmentation cystoplasty form the cornerstone of long-term management. Fertility and ejaculatory function appear relatively preserved even following bladder neck procedures.
Conclusion: PUV is a chronic multisystem condition demanding lifelong surveillance. A structured transitional care model—incorporating coordinated paediatric and adult urology, nephrology, and allied health input—is essential to optimise bladder safety, preserve residual renal function, and address the psychosocial dimensions of this condition in young adulthood.
Keywords: posterior urethral valves; transitional care; valve bladder syndrome; chronic kidney disease; urodynamics; paediatric urology; end-stage renal disease; transurethral valve ablation.
Introduction
Posterior urethral valves (PUV) represent the most clinically significant congenital obstructive uropathy in male patients, accounting for the majority of cases of severe obstructive nephropathy in boys.[1,2] The condition is characterised by anomalous mucosal leaflets arising from the verumontanum and extending anterolaterally to obstruct the posterior urethra, creating a functional and anatomical barrier to urinary outflow that begins to exert its pathological effects during critical periods of renal and bladder organogenesis in utero.[3]
Epidemiologically, PUV occurs in approximately 1 in 3000 to 8000 male live births, though milder phenotypes may remain undetected until later in childhood or even adulthood.[4,5] The introduction of routine antenatal ultrasound surveillance from the early 1980s onwards transformed the diagnostic landscape, enabling prenatal identification of the majority of affected pregnancies based on characteristic sonographic features including bilateral hydro-ureteronephrosis, a thickened trabeculated bladder, dilatation of the posterior urethra (the 'keyhole sign'), and, in severe cases, oligohydramnios.[6,7]
Historically, PUV carried a significant early mortality burden; however, improvements in neonatal intensive care, refinements in endoscopic technique, and multidisciplinary perinatal management have shifted the principal clinical concern from acute survival to the long-term trajectory of renal and bladder function.[8] As a consequence, the contemporary paediatric urologist encounters an expanding cohort of adolescents and young adults who require structured, evidence-based transitional care to mitigate the ongoing risks of bladder dysfunction and progressive nephropathy.[9]
This narrative review presents a contemporary synthesis of the evidence base governing PUV management across the lifespan. It examines prenatal predictors of outcome, neonatal and paediatric surgical strategies, the pathophysiology and clinical spectrum of valve bladder syndrome, risk stratification for chronic kidney disease (CKD) and end-stage renal disease (ESRD), and the particular challenges inherent in the transition from paediatric to adult urological care.
Prenatal Diagnosis and Antenatal Interventions
Antenatal ultrasound has become the primary modality through which PUV is first suspected. The combination of megacystis, bilateral hydro-ureteronephrosis, a dilated posterior urethra, and a thickened bladder wall constitutes a highly sensitive sonographic constellation for the diagnosis, though none of these features is entirely specific.[6] Conditions such as bilateral high-grade vesicoureteral reflux (VUR), prune belly syndrome, urethral atresia, and obstructing ureterocele may produce overlapping imaging phenotypes, necessitating careful postnatal diagnostic evaluation regardless of antenatal impression.[7]
Among prenatal sonographic findings, the severity of oligohydramnios carries the most significant prognostic weight. Progressive reduction in amniotic fluid volume reflects impaired fetal urinary output and correlates with both pulmonary hypoplasia and adverse renal outcomes.[10,11] Additional markers of poor prognosis include increased renal cortical echogenicity, cortical cysts, and the presence of marked bilateral upper tract dilatation.[12] These findings reflect underlying dysplastic renal parenchyma, the degree of which ultimately determines long-term renal functional reserve irrespective of the success of postnatal obstruction relief.
In cases of severe lower urinary tract obstruction with evolving oligohydramnios, antenatal intervention via percutaneous vesicoamniotic shunting has been employed with the aim of decompressing the obstructed bladder, restoring amniotic fluid volume, and halting progressive renal insult.[13] Cystoscopic fetal valve ablation has also been described in selected centres.[14]
The PLUTO randomised controlled trial, which remains the only completed randomised evaluation of prenatal intervention for lower urinary tract obstruction, demonstrated improved survival in shunted fetuses but found that only approximately one-third of shunted survivors had normal renal function at one year of age.[13] These findings highlight the fundamental limitation of antenatal intervention: obstruction relief cannot reverse established renal dysplasia. Furthermore, procedural risks including preterm labour, failed shunt placement, and fetal demise must be carefully weighed against uncertain functional benefit.[15]
Current evidence supports antenatal intervention only in carefully selected cases with a reasonable expectation of renal preservation, and ongoing research efforts are directed at refining selection criteria through fetal urine biochemistry, magnetic resonance imaging, and novel biomarkers of renal tubular maturity.[15,16]
Neonatal and Early Surgical Management
Where PUV is suspected antenatally, particularly in the context of oligohydramnios or bilateral severe hydronephrosis, delivery at a tertiary centre with immediate access to neonatal intensive care and paediatric urological expertise is advisable.[8] Pulmonary hypoplasia secondary to oligohydramnios may necessitate respiratory support in the immediate neonatal period. Initial urinary tract decompression is typically achieved with a small-calibre urethral catheter, pending definitive surgical management once the infant is haemodynamically stable.
A critical and frequently underappreciated aspect of early neonatal management is post-obstructive diuresis. Relief of chronic bladder outlet obstruction triggers a physiological natriuresis and aquaresis that, if not anticipated and corrected, can result in significant hyponatraemia, hypovolaemia, and metabolic derangement.[17,18] Meticulous fluid and electrolyte management in conjunction with the neonatal intensive care team and paediatric nephrology is therefore integral to safe perioperative care.
Endoscopic transurethral valve ablation is the established definitive treatment for PUV in neonates and infants who are sufficiently large to accommodate a paediatric cystoscope or resectoscope.[19] Ablation is performed at the 5, 7, and 12 o'clock positions using a hooked cold knife, electrical Bugbee electrode, or laser energy source. The majority of treated infants demonstrate subsequent resolution or improvement of upper urinary tract dilatation.
Assessment of ablation adequacy is conventionally performed with a voiding cystourethrogram (VCUG) four to twelve weeks postoperatively.[20] Residual valve leaflets requiring re-resection are encountered in seven to fifteen percent of cases in contemporary series.[21,22] Longer-term complications of valve ablation include urethral stricture formation and, less commonly, urinary incontinence attributable to sphincteric injury at the site of incision.[23]
In very small or premature neonates whose urethral calibre precludes safe cystoscopy, cutaneous vesicostomy provides effective temporary bladder decompression.[8] The role of vesicostomy in optimising long-term bladder function remains contested. Certain studies suggest that prolonged bladder defunctionalisation is associated with reduced ultimate bladder capacity and diminished wall compliance compared with primary valve ablation,[24,25] while other investigators have not demonstrated equivalent detriment.[26]
Supravesical diversion through ureterostomy or pyelostomy is reserved for highly selected cases with ongoing deterioration despite vesicostomy and carries its own risks of upper tract damage and future reconstructive complexity.
Bladder Dysfunction: Pathophysiology and Clinical Spectrum
Despite technically successful ablation of obstructing valve leaflets, a substantial proportion of boys with PUV continue to exhibit significant bladder dysfunction attributable to intrinsic changes in detrusor morphology and neural regulation induced by prolonged prenatal and early postnatal obstruction.[27] This phenomenon, termed 'valve bladder syndrome' following its characterisation in the early 1980s, encompasses a spectrum of dysfunctional voiding patterns that persist or evolve even after the mechanical obstruction has been relieved.[27]
The underlying pathophysiology involves obstruction-induced myocyte hypertrophy, interstitial fibrosis, altered collagen composition, and disruption of normal detrusor innervation, collectively resulting in a bladder that may be hypercontractile, poorly compliant, or hypocontractile depending on disease severity and the age at assessment.[28,29] Clinically, valve bladder syndrome may manifest as urinary incontinence, recurrent urinary tract infections (UTIs), persistent upper tract dilatation despite patent outflow, and progressive renal impairment attributable to high-pressure bladder storage.
Urodynamic evaluation is indispensable in characterising bladder dysfunction in PUV patients and guiding individualised management decisions.[30] Patients are broadly categorised into three urodynamic phenotypes: hyperreflexia bladder (involuntary detrusor contractions, reduced functional capacity), small hypocompliant bladder (elevated storage pressures with reduced volume), and myogenic failure (impaired contractility with overflow incontinence and elevated post-void residual volumes).[28]
Importantly, the dominant urodynamic phenotype is not static. Longitudinal studies demonstrate that bladders with pronounced detrusor overactivity in infancy and early childhood frequently transition toward hypocontractility as the patient ages through adolescence into adulthood.[31] This evolution has critical implications for transitional care, as management strategies appropriate for a hyperreflexic bladder may be detrimental if applied to a patient who has developed myogenic failure. Periodic urodynamic reassessment, particularly at key developmental transitions, is therefore essential.
Oral anticholinergic agents remain the pharmacological cornerstone for managing detrusor overactivity and poor bladder compliance in PUV patients during childhood.[32] Alpha-adrenergic antagonists may reduce bladder outlet resistance and improve voiding efficiency, particularly in patients with functional bladder neck obstruction.[33]
Nocturnal polyuria, defined as hypo-osmolar urine output exceeding 30 mL/kg per day, represents a specific management challenge in PUV patients with impaired urinary concentrating ability secondary to renal tubular damage.[34] Nocturnal bladder emptying via an indwelling catheter or clean intermittent catheterisation (CIC) before sleep reduces overnight storage volumes and intravesical pressures, thereby protecting the upper tracts from the consequences of nocturnal high-pressure distension.[34]
Intradetrusor injection of onabotulinumtoxinA has emerged as an effective therapeutic option for patients with refractory detrusor overactivity or poor compliance who are not responding to oral pharmacotherapy.[35] The procedure is well-tolerated in the paediatric population and may defer or obviate the need for more invasive surgical reconstruction.
4 Surgical Management of Refractory Bladder Dysfunction
When conservative and pharmacological measures fail to achieve safe bladder storage pressures and adequate emptying, surgical reconstruction may be necessary.[36] Augmentation cystoplasty, most commonly utilising a detubularised segment of ileum or sigmoid colon, effectively increases bladder capacity and reduces storage pressures, protecting the upper urinary tracts and transplanted kidneys where applicable.[37]
The creation of a continent catheterisable channel (Mitrofanoff principle, utilising the appendix or tapered ileum) frequently accompanies augmentation, particularly in patients who are unable or unwilling to perform urethral CIC.[37] Patients who undergo augmentation cystoplasty require indefinite surveillance for complications including mucus retention, recurrent UTIs, metabolic acidosis, bladder calculi, and the small but non-negligible long-term risk of secondary malignancy within the augmented segment.
In the young adult population specifically, voiding dysfunction attributable to functional bladder neck obstruction may warrant a trial of alpha-adrenergic blockade prior to consideration of bladder neck incision. The latter carries risks of retrograde ejaculation and incontinence and should be preceded by video urodynamic confirmation of elevated voiding pressures in the context of a closed bladder neck.[38]
Renal Outcomes and Risk Stratification
Renal impairment represents the most consequential long-term morbidity associated with PUV, with a recent systematic review and meta-analysis reporting that approximately 22% of PUV patients develop CKD and 11% progress to ESRD.[39] Children at highest risk tend to reach ESRD during the first decade of life, with progression to renal replacement therapy occurring at a mean age of approximately eight years in the most severely affected cohort.[40]
Several clinical and biochemical parameters have been identified as reliable predictors of long-term renal outcome in PUV patients.[39,40] A postnatal nadir serum creatinine above 1.0 mg/dL during the first year of life is among the most consistently cited prognostic markers for future renal insufficiency.[40] Renal cortical echogenicity on the first postnatal ultrasound, reflecting the degree of underlying dysplasia, similarly confers independent prognostic significance.[41] Persistent bladder dysfunction with elevated intravesical storage pressures, and ongoing febrile UTIs, contribute to progressive nephron loss in patients who already have limited renal reserve.
VUR is present in approximately 50% of boys with PUV. While high-grade reflux in the context of obstructive uropathy increases the risk of pyelonephritis and renal scarring, evidence that VUR independently predicts ESRD—independent of underlying renal dysplasia and bladder dysfunction—remains inconsistent.[42,43,44] Nevertheless, its detection warrants prophylactic antibiotic therapy during the first year of life, with consideration of circumcision as an adjunctive risk-reduction strategy given the significant reduction in febrile UTI risk demonstrated in retrospective series.[45,46]
Children and adolescents with PUV-associated CKD require integrated nephrological surveillance encompassing monitoring of glomerular filtration rate trajectory, blood pressure, anaemia, metabolic acidosis, calcium-phosphate homeostasis, and linear growth.[47] Angiotensin-converting enzyme inhibition or angiotensin receptor blockade may confer nephroprotective benefit in proteinuric patients through haemodynamic and anti-fibrotic mechanisms, though evidence specific to the PUV population remains limited.
The fundamental urological contribution to renal preservation is ensuring that the bladder operates as a low-pressure reservoir with efficient, complete emptying.
The principles of safe bladder management—low-pressure storage and unobstructed outflow—must underpin every aspect of long-term urological care in this population, as failure to achieve these goals constitutes a modifiable risk factor for renal deterioration at any age.[30,38]
Transitional Care: Challenges and Frameworks
Transition from paediatric to adult medical care represents a period of particular vulnerability for young people with chronic conditions, and PUV is no exception. Adolescents and young adults navigating this transition face multiple simultaneous pressures including educational demands, social development, evolving independence, and, frequently, a relative disengagement from healthcare systems.[48]
Specific urological risks during this period include unrecognised deterioration in bladder function as urodynamic phenotype evolves, loss to follow-up prior to nephrological referral for advancing CKD, inadequate surveillance of augmentation cystoplasty, and inadequate communication of disease-specific information to receiving adult clinicians unfamiliar with the complex PUV history.[9,48]
When a young adult with a history of PUV presents to an adult urologist, a comprehensive assessment is warranted regardless of the patient's perceived degree of wellness. This assessment should encompass a thorough voiding history including incontinence, nocturia, frequency, and straining; a validated symptom questionnaire; a frequency-volume voiding diary; and focused examination.[38]
Baseline investigations should include serum creatinine and estimated glomerular filtration rate, electrolytes, urine dipstick and culture, and upper tract imaging with renal ultrasound. Urodynamic evaluation—and videourodynamics where bladder neck dysfunction is suspected—should be strongly considered in any PUV patient presenting with voiding dysfunction or evidence of new or progressive upper tract dilatation.[30,38] A published algorithm from the European Association of Urology and European Society for Paediatric Urology provides a structured framework for the long-term surveillance of PUV patients.[30]
Fertility and ejaculatory function appear to be relatively well-preserved in the majority of men with a history of PUV, even among those who underwent bladder neck procedures in infancy.[49] Nonetheless, young men with PUV should receive appropriate counselling regarding their reproductive health, the potential contribution of renal impairment or immunosuppressive therapy (in transplant recipients) to fertility, and contraceptive considerations in the context of their chronic condition.
The psychosocial burden of living with PUV and its sequelae—including urinary incontinence, catheter dependence, stoma management, renal transplantation, and the psychological impact of chronic disease during adolescence—should not be underestimated. Transition programmes that incorporate psychological support, peer networks, and structured education about self-management have demonstrated improved engagement with adult care services in analogous paediatric chronic disease populations.[48]
Conclusion
Posterior urethral valves represent a lifelong chronic condition in which the trajectory of both bladder function and renal reserve is shaped by a complex interplay of congenital dysplasia, surgical history, ongoing bladder dynamics, and the adequacy of surveillance at each developmental stage. The expanding survivor cohort—a product of improved prenatal detection and neonatal care—presents both an opportunity and an obligation for the urological community to develop and implement structured transitional care pathways that ensure continuity of high-quality, evidence-informed management into adulthood.
Future research priorities include the development and validation of predictive biomarkers to enable earlier identification of patients at highest risk of ESRD, optimisation of prenatal selection criteria for fetal intervention, refinement of the timing and indications for surgical bladder reconstruction, and prospective evaluation of dedicated PUV transition programmes on long-term clinical and patient-reported outcomes. A multidisciplinary team comprising paediatric and adult urologists, paediatric and adult nephrologists, continence nurse specialists, and allied health professionals is the optimal configuration for addressing the full complexity of this condition across the lifespan.
Declarations
Author contribution: VV conceived, drafted, and critically revised the manuscript in its entirety.
Competing interests: None declared.
Funding: None.
Ethical approval: Not applicable (narrative review).
Patient consent: Not applicable.
References